Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OnQ (bupivacaine)
- Development stage
- Approved
- Lead developer
- Avanos Medical
- Modality
- Small Molecules
- Administration
- Percutaneous
01
Overview
On-Q (also written ON-Q) is a continuous wound infusion system, specifically the On-Q Pain Relief System, designed for postoperative pain management. It is a drug-device combination consisting of a disposable elastomeric pump that delivers a continuous infusion of bupivacaine, a long-acting local anesthetic, through thin catheters placed directly into or adjacent to a surgical wound. Bupivacaine acts as a voltage-gated sodium channel blocker, inhibiting the influx of sodium ions into nerve cells, which prevents the initiation and conduction of nerve impulses and results in localized anesthesia. Originally developed by I-Flow Corporation (now part of Avanos Medical), the On-Q system is used in various surgical settings, such as DIEP free flap breast reconstruction, to provide effective analgesia and reduce the reliance on systemic opioids.
- Brand names
- On-QOn-Q Pain Relief SystemOn-Q PainBuster
- Other names
- ON-Q pain relief pumpON-Q pain management system
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)SCN5A (Sodium channel protein type 5 subunit alpha)Kir (Inward-rectifier potassium channels)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on OnQ (bupivacaine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OnQ (bupivacaine).